A US Food and Drug Administration advisory committee overwhelmingly endorsed a new heart failure indication for Novartis AG’s Entresto (sacubitril/valsartan) but was more divided on how to define the target population for that new claim.
On 15 December, the Cardiovascular and Renal Drugs Advisory Committee voted 12-1 that the results of the PARAGON-HF study in...





